Diabetes and everolimus-eluting stents: What we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial

Chiara Bernelli; Georgina Fuertes Ferre; Alaide Chieffo

doi:10.1586/erc.12.183

Diabetes and everolimus-eluting stents: What we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial

Chiara Bernelli, Georgina Fuertes Ferre, Alaide Chieffo

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article

Abstract

Evaluation of: Jensen LO, Thayssen P, Junker A et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus and sirolimus-eluting stents (from the SORT OUT IV trial). Am. J. Cardiol. 110(11), 1585-1591 (2012). Percutaneous coronary interventions in diabetic patients are still challenging in the drug-eluting stents era because of the more extensive coronary artery disease and the presence of comorbidities. New-generation drug-eluting stents have demonstrated an improved efficacy and safety in patients treated with percutaneous coronary interventions. The SORT OUT IV substudy has investigated the clinical impact of the everolimus-eluting stents versus sirolimus-eluting stents in both the diabetic and nondiabetic population.

Original language	English
Pages (from-to)	151-154
Number of pages	4
Journal	Expert Review of Cardiovascular Therapy
Volume	11
Issue number	2
DOIs	https://doi.org/10.1586/erc.12.183
Publication status	Published - Feb 2013

Fingerprint

Keywords

diabetes mellitus
drug-eluting stents
major adverse cardiac events
percutaneous coronary intervention

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Internal Medicine

Cite this

Bernelli, C., Ferre, G. F., & Chieffo, A. (2013). Diabetes and everolimus-eluting stents: What we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial. Expert Review of Cardiovascular Therapy, 11(2), 151-154. https://doi.org/10.1586/erc.12.183

@article{b15cbff7a1634599a5f28319633ab846,

title = "Diabetes and everolimus-eluting stents: What we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial",

abstract = "Evaluation of: Jensen LO, Thayssen P, Junker A et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus and sirolimus-eluting stents (from the SORT OUT IV trial). Am. J. Cardiol. 110(11), 1585-1591 (2012). Percutaneous coronary interventions in diabetic patients are still challenging in the drug-eluting stents era because of the more extensive coronary artery disease and the presence of comorbidities. New-generation drug-eluting stents have demonstrated an improved efficacy and safety in patients treated with percutaneous coronary interventions. The SORT OUT IV substudy has investigated the clinical impact of the everolimus-eluting stents versus sirolimus-eluting stents in both the diabetic and nondiabetic population.",

keywords = "diabetes mellitus, drug-eluting stents, major adverse cardiac events, percutaneous coronary intervention",

author = "Chiara Bernelli and Ferre, {Georgina Fuertes} and Alaide Chieffo",

year = "2013",

month = feb

doi = "10.1586/erc.12.183",

language = "English",

volume = "11",

pages = "151--154",

journal = "Expert Review of Cardiovascular Therapy",

issn = "1477-9072",

publisher = "Expert Reviews Ltd.",

number = "2",

}

TY - JOUR

T1 - Diabetes and everolimus-eluting stents

T2 - What we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial

AU - Bernelli, Chiara

AU - Ferre, Georgina Fuertes

AU - Chieffo, Alaide

PY - 2013/2

Y1 - 2013/2

N2 - Evaluation of: Jensen LO, Thayssen P, Junker A et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus and sirolimus-eluting stents (from the SORT OUT IV trial). Am. J. Cardiol. 110(11), 1585-1591 (2012). Percutaneous coronary interventions in diabetic patients are still challenging in the drug-eluting stents era because of the more extensive coronary artery disease and the presence of comorbidities. New-generation drug-eluting stents have demonstrated an improved efficacy and safety in patients treated with percutaneous coronary interventions. The SORT OUT IV substudy has investigated the clinical impact of the everolimus-eluting stents versus sirolimus-eluting stents in both the diabetic and nondiabetic population.

AB - Evaluation of: Jensen LO, Thayssen P, Junker A et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus and sirolimus-eluting stents (from the SORT OUT IV trial). Am. J. Cardiol. 110(11), 1585-1591 (2012). Percutaneous coronary interventions in diabetic patients are still challenging in the drug-eluting stents era because of the more extensive coronary artery disease and the presence of comorbidities. New-generation drug-eluting stents have demonstrated an improved efficacy and safety in patients treated with percutaneous coronary interventions. The SORT OUT IV substudy has investigated the clinical impact of the everolimus-eluting stents versus sirolimus-eluting stents in both the diabetic and nondiabetic population.

KW - diabetes mellitus

KW - drug-eluting stents

KW - major adverse cardiac events

KW - percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=84873892250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873892250&partnerID=8YFLogxK

U2 - 10.1586/erc.12.183

DO - 10.1586/erc.12.183

M3 - Article

C2 - 23405836

AN - SCOPUS:84873892250

VL - 11

SP - 151

EP - 154

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 2

ER -

Access to Document

10.1586/erc.12.183